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ABSTRACT
Numerous lines of evidence support the role of oxid-
ative stress in different types of cancer. A major DNA
lesion, 8-oxo-7,8-dihydroguanine (8-oxoG), is formed
by reactive oxygen species in the genome under
physiological conditions. 8-OxoG is strongly muta-
genic, generating G C!T A transversions, a frequent
somatic mutation in cancers. hOGG1 was cloned as a
gene encoding a DNA glycosylase that specifically
recognizes and removes 8-oxoG from 8-oxoG:C
base pairs and suppresses G C!T A transversions.
Inthisstudy,weinvestigatedthesubcellularlocaliza-
tion and expression of hOGG1 during the cell cycle.
Northern blots showed cell-cycle-dependent mRNA
expression of the two major hOGG1 isoforms. By
using a cell line constitutively expressing hOGG1
fused to enhanced green fluorescence protein
(EGFP), we observed a dynamic relocalization of
EGFP-hOGG1 to the nucleoli during the S-phase of
the cell cycle, and this localization was shown to be
linkedtotranscription.AC/Gchangethatresultsinan
amino acid substitution from serine to cysteine in
codon326hasbeenreportedasageneticpolymorph-
ism and a risk allele for a variety of cancers. We
investigated the cellular localization of the corres-
ponding protein, hOGG1-Cys
326, fused to EGFP and
observed a dramatic effect on its localization that is
explained by a change in the phosphorylation status
of hOGG1.
INTRODUCTION
Oxidative damage to DNA is generated by reactive oxygen
species that arise both endogenously and from exposure to
environmental mutagens or ionizing radiation. Oxidative
DNA damage has been implicated in a number of patho-
physiological processes, including degenerative diseases, can-
cer and ageing (1–6). 7,8-Dihydro-8-oxoguanine (8-oxoG) is
one of the most important oxidative lesions produced, which
has a highly mutagenic effect owing to its bias to mispair with
A residues thereby generating G C!T A transversion muta-
tions in repair-deﬁcient bacterial and yeast cells (7–10).
8-OxoG is mainly repaired by the base excision repair
(BER) mechanism. BER is a multistep process that involves
the sequential activity of several proteins, initiated by a DNA
glycosylase that recognizes and removes the damaged base
(11,12). The human OGG1 gene encodes a DNA glycosylase/
AP-lyase that is responsible for removing 8-oxoG from
8-oxoG:C base pairs in double-stranded DNA. The hOGG1
enzyme has been thoroughly characterized and the crystal
structure of the catalytic core of hOGG1 bound to 8-
oxoG:C containing DNA as well as the native enzyme have
been solved (13–18). The gene is expressed in at least 12
different alternative spliced forms, with products being direc-
ted both to the nucleus and to the mitochondria (14,19–23).
High levels of 8-oxoG have been reported in several kinds
ofhumancancertissues, including lung,renal, breastand colo-
rectal carcinomas, as compared with their non-tumorous coun-
terparts (24–27). Accumulation of up to 7-fold higher levels of
8-oxoG and an increase in spontaneous mutation frequency
has been reported for two independently obtained OGG1
 / 
mice (28,29), Furthermore, a predisposition towards the devel-
opmentoflungadenoma/carcinomahasbeendemonstratedfor
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 /  mice (30). A report on the ability of hOGG1 to
suppress G C!T A transversions in human cells in vivo
strengthens the idea that hOGG1 is a critical factor in prevent-
ing mutations in human cells (31). Therefore, defects in
hOGG1 that affect its repair capability might have an involve-
ment in carcinogenesis by enhancing the mutation rates of key
genes, such as oncogenes or tumour suppressor genes.
Among several HOGG1 alleles described, a C/G poly-
morphism at position 1245 in exon 7 of the HOGG1 gene
results in the substitution of a serine for a cysteine in codon
326. Among several studies carried out to determine whether
hOGG1 is a risk factor for several cancer types (32–45), few
have indicated that the hOGG1-Cys
326 might be a risk allele
for a variety of cancers (38–40,43–45). Ambiguous results
have been obtained on the effect of such an amino acid change
on the DNA repair activity of the resulting mutant hOGG1-
Cys
326 protein compared with the wild-type hOGG1 protein.
On the basis of an Escherichia coli complementation assay,
one study showed that the hOGG1 protein encoded by the
wild-type allele exhibited substantially higher DNA repair
activity than the hOGG1-Cys
326 variant (20), while a second
study showed that both forms of the enzyme played an equal
role (33). Furthermore, no differences in catalytic activities
were observed in two independent studies (33,46).
Although the biochemical properties of hOGG1 are well
deﬁned, the biological role of OGG1 in mammalian cells
and its possible involvement in carcinogenesis is still poorly
understood. In order to elucidate the cellular role of hOGG1
we have investigated both the expression of hOGG1 and its
cellular distribution. Using enhanced green ﬂuorescent protein
(EGFP) as a reporter gene we show that hOGG1 is localized in
the nucleoli during the S-phase of the cell cycle. Furthermore,
the nucleolar localization of EGFP-hOGG1 is linked to
transcription.Wealso investigatedthe localizationofthe poly-
morphic form of hOGG1 harbouring the serine to cysteine
mutation at codon 326 and show that there is a dramatic
change on the subcellular localization of the mutant protein
as it is transported to the nucleus but is excluded from the
nucleoli. We have previously shown that hOGG1 is associated
with the soluble chromatin and the nuclear matrix during
interphase and with condensed chromatin during mitosis
(47). These associations are also disrupted in the mutant pro-
tein. Interestingly, this serine residue lies within a predicted
site of potential phosphorylation, close to the nuclear local-
ization signal. Finally, by mimicking a hOGG1 protein phos-
phorylated atSer-326wedemonstratethattheregulationofthe
nucleolar localization, soluble chromatin, nuclear matrix and
condensed chromatin association of hOGG1 are mediated
through the phosphorylation of Ser-326.
MATERIALS AND METHODS
Synchronization of HaCat cells, mRNA isolation and northern
blothybridizationwerecarriedout asdescribedpreviously(48).
Site-directed mutagenesis of hOGG1
Full-length hOGG1 cDNA cloned into pEGFP-N1 vector
(pHOGH1-EGFP-12) as described previously (14), represents
the wild-type hOGG1 construct, referred to as pEGFP-
hOGG1. The QuikChange site-directed mutagenesis kit
(Stratagene) was used to introduce the Ser
326Cys (pEGFP-
hOGG1-Cys
326), the Ser
326Ala (pEGFP-hOGG1-Ala326) and
the Ser
326Glu (pEGFP-hOGG1-Glu
326) mutations with
pHOGH1-EGFP-12 construct as the parental vector according
to the manufacturer’s protocol. The cloned fragments were
sequenced and the desired mutations were thus veriﬁed.
The pEYFP-hOGG1 plasmid was constructed by ligating
the hOGG1 cDNA fragment from pEGFP-hOGG1 into the
pEYFP-N1 vector. The pECFP-PCNA and the HcRed-
PCNA are described in (49) and (50), respectively.
Cell culture, DNA transfection and selection of
stable cell lines
HeLa S3 cells were cultivated in DMEM with 4.5 g/l glucose,
10% FCS, 0.3 mg/ml glutamine, 100 U/ml penicillin and
0.1 mg/ml streptomycin at 37 C in a 5% CO2 air atmosphere.
Transfections of HeLa S3 cells were performed using
FuGENE 6 Transfection Reagent (Roche Molecular Biochem-
icals) according to the manufacturer’s recommendations. To
generate stable cell lines, 8 · 10
5 HeLa S3 cells were plated in
100 mm culture dishes. After overnight incubation, cells were
transfected with pEGFP-hOGG1, pEGFP-hOGG1-Cys
326,
pEGFP-hOGG1-Glu
326 and pEGFP-N1. After 2 days, each
plate was subcultured into six 100 mm culture dishes. Cells
were grown overnight and 800 mg/ml geneticin was added.
Single green ﬂuorescent clones were isolated after 20 days.
Nuclear protein extracts, western blot and assay
for faPy DNA glycosylase activity
Nuclear extracts from HeLa-EGFP, HeLa-EGFP-hOGG1,
HeLa-EGFP-hOGG1-Cys
326 and pEGFP-hOGG1-Glu
326
were prepared as described previously (28). For western
blot analysis, 20 mg nuclear protein extracts were separated
by SDS–PAGE and transferred onto a nitrocellulose mem-
brane. To detect EGFP and EGFP-hOGG1 (and the mutants)
the membrane was probed with a polyclonal anti-GFP anti-
body (ab290-50; Abcam), and to detect EGFP-hOGG1 (and
the mutants) a monoclonal anti-human OGG1 antibody (clone
7E2; IBL) was used. FaPy DNA glycosylase assay using
increasing amounts of nuclear extracts was carried out as
described previously (48).
Cell-cycle synchronization, flow cytometry and
immunofluorescence
HeLa-EGFP-hOGG1 and HeLa-EGFP were synchronized at
the G1/S boundary by two cycles of thymidine blockage and at
the G2/M boundary by nocodazole treatment. Brieﬂy, expo-
nentially growing cells were blocked for 16 h in 2 mM thy-
midine containing DMEM, released for 9 h in thymidine-free
DMEM and blocked again with 2 mM thymidine containing
DMEM for another 16 h. Synchronization at G2/M was
achieved by culturing the cells with nocodazole (40 ng/ml)
for 16 h. After the double-thymidine block and the removal of
nocodazole, the cells were allowed to progress under normal
conditions and harvested at different time points after release.
The cell-cycle phase distribution of a cell population was
determined by measuring cell DNA contents by ﬂow cyto-
metry as follows: cells (1 · 10
6) were trypsinized, washed
and ﬁxed in 75% ice-cold ethanol and stored at 4 C. Imme-
diately before ﬂow cytometric analysis, the samples were
1814 Nucleic Acids Research, 2005, Vol. 33, No. 6treated with RNase A for 30 min at room temperature and then
stained with propidium iodide (ﬁnal concentration 50 mg/ml)
for 30 min at 37 C. The samples were analysed by using a BD
LSR ﬂow cytometer (Becton Dickinson, NJ). For immuno-
ﬂuorescence, cells were grown on glass coverslips and ﬁxed
with 4% paraformaldehyde for 20 min at room temperature at
different time points after release. Cellular DNA was stained
with 0.25 mg/ml 40,60-diamino-2-phenylindole (DAPI) for
10 min at room temperature. Coverslips were mounted with
ﬂuorescent mounting medium (DAKO) and visualized using a
Zeiss Axioplan 2 ﬂuorescence microscope (Carl Zeiss, Jena,
Germany).
Immunostaining and confocal analysis
DNA labelling and staining with 5-bromo-20-deoxyuridine
(BrdU labelling and detection kit I; Boehringer Mannheim,
Germany) was performed according to the manufacturer’s
instructions. The nucleoli were detected with an anti-
nucleolin antibody (clone 3G4B2; Upstate biotechnology,
Lake Placid, NY) on cells ﬁxed in 2% formalin for 10 min
followed by permeabilization with ice-cold methanol for
30 min. The secondary antibody used for both BrdU and
nucleoli staining was a rhodamine (tetra-methyl)-conjugated
goat anti-mouse antibody (T-2762) from Molecular Probe
(Eugene, OR). The cells were examined in a Zeiss LSM 510
laser scanning microscope equipped with a Plan-Apochromate
63·/1.4 oil immersion objective. We used the 488 nm laser
line for excitation of EGFP (detected at 505 nm <l EGFP <
530 nm) and the 543 nm laser line for rhodamine (tetra-
methyl) (detected at lRhodamine > 560 nm). ECFP fusion pro-
tein was excited with a 458 nm laser line (detected at
480 nm <l ECFP < 520 nm), EYFP fusion protein was excited
with a 514 nm laser line (lEGFP > 560 nm) and HcRed fusion
protein was excited with a 543 nm laser line and detected at
>585or650nm.Theimageswerefrom1mmthickslicesofthe
cells. The images were exported into Adobe Photoshop
(Adobe Systems Inc., San Jose, CA).
Actinomycin D treatment
For actinomycin D treatment, HeLa-EGFP-hOGG1 cells were
grown on chamber slides and synchronized at the G1/S bound-
ary by two cycles of thymidine blockage. Cells were allowed
to enter S-phase and actinomycin D was added 1 h after block
release and incubated for 4 and 5 h, respectively. Cells were
thenwashedtwicewith phosphate-bufferedsaline(PBS),ﬁxed
with 96% ethanol (anti-nucleolin) for 10 min at room temper-
ature or 4% PFA (anti-ﬁbrillarin and anti-RPA135) for 20 min
and permeabilized with 0.5% Triton X-100 for 5 min at 4 C
and washed again with PBS. Cells were air-dried before
incubation with primary and secondary antibodies diluted in
PBS with 1% BSA. As primary antibody monoclonal anti-
nucleolin (clone 3G4B2; Upstate Biotechnology), RPA40
(N-20) (sc-17700; Santa Cruz), RPA135 (N-17) (sc-17913;
Santa Cruz) and anti-ﬁbrillarin (AFB01, cytoskeleton) were
used and incubated overnight at room temperature. Incubation
with secondary antibody (Alexa 594, 590/617; Molecular
Probes) was carried out for 30 min at room temperature.
DNA was stained with DAPI for 10 min at room temperature.
Slides were mounted using the DAKO ﬂuorescence mounting
medium and examined using a Zeiss Axioplan 2 ﬂuorescence
microscope. Images were obtained using CoolSNAP (Photo-
metrics) and then processed for publication using Jasc Pain
Shop Pro (Jasc software).
Nuclear matrix preparation
Nuclear matrix proteins were fractionated from the indicated
cells as described previously (47). For western blot analyses,
equal cell equivalents from each fraction were subjected to 8%
SDS–PAGE and probed with appropriate antibodies: rabbit
polyclonal anti-GFP antibody (ab 290-50; Abcam), goat poly-
clonal anti-lamin A/C antibody (N-18; Santa Cruz), goat
polyclonal anti-histone H1 antibody (C-17; Santa Cruz),
monoclonal anti-human OGG1 antibody (clone 7E2; IBL)
and rabbit polyclonal anti-phosphoserine antibody (poly-Z-
PS1; Zymed Laboratories).
RESULTS
Cell-cycle-dependent expression of HOGG1 gene
The cell-cycle-dependent expression of HOGG1 was followed
by northern blot hybridization of poly(A)
+ RNA isolated from
synchronized HaCat cells. Progression throughout the cell
cycle was monitored by [
3H]thymidine incorporation, which
started to increase 12 h after serum addition and reached a
peak at 25 h (Figure 1A). Northern blots revealed two mRNA
bands of  2.0 and 2.4 kb, representing the transcripts of the
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Figure 1. Cell-cycle-dependent expression of hOGG1 mRNA in synchronized
HaCatcells.DNAsynthesisandmRNAlevelsweremeasuredat0,8,12,17,25
and32hafterserumadditiontoserum-starvedHaCatcells.(A)Incorporationof
3H-labelled thymidine during 25 min incubation. (B) Northern blot analysis of
hOGG1 and b-actin expression as indicated.
Nucleic Acids Research, 2005, Vol. 33, No. 6 1815nuclear and mitochondrial isoforms, respectively (Figure 1B).
Expression of both isoforms increased during S-phase and
into G2.
hOGG1 is sorted to the nucleoli during S-phase
Studies of transiently transfected HeLa cells with the reporter
protein EGFP fused to the C-terminal of hOGG1 have previ-
ously shown that the enzyme is transported to the nucleus (14).
These studies revealed a heterogeneous population of cells
displaying either homogeneous or reminiscent nucleolar loc-
alization of hOGG1. To conﬁrm the nucleoli localization of
EGFP-hOGG1, cells were ﬁxed and nucleoli were visualized
by confocal microscopy using antibodies against nucleolin.
When the signals from EGFP-hOGG1 and anti-nucleolin
were merged, EGFP-hOGG1 was found to be concentrated
predominantly within the nucleoli as shown in Figure 2A.
Furthermore, we established stable HeLa cell lines carrying
either EGFP alone or EGFP-hOGG1 fusion proteins to further
study the nuclear sublocalization of hOGG1 during the cell
cycle. Overexpression of EGFP and EGFP-hOGG1 in the
stable cell lines was examined in nuclear extracts by western
blot using anti-OGG1 and anti-GFP speciﬁc antibodies. EGFP
(30 kDa), EGFP-hOGG1, EGFP-hOGG1-Cys
326 and EGFP-
hOGG1-Glu
326 (68 kDa) were recognized by the anti-GFP
speciﬁc antibody (Figure 3A) while only EGFP-hOGG1,
EGFP-hOGG1-Cys
326 and EGFP-hOGG1-Glu
326 (68 kDa)
were recognized by the anti-OGG1 speciﬁc antibody
(Figure 3B). Nuclear extracts from HeLa-EGFP and HeLa-
EGFP-hOGG1 were tested for faPy DNA glycosylase activity
to demonstrate the functionality of the fusion protein product.
Results showed that hOGG1 fused to the EGFP was catalyt-
ically active (Figure 3C).
Cells were synchronized by nocodazole, which causes the
cells to arrest at the G2/M boundary, or by the double-
thymidine block, which arrest the cells at G1/S boundary.
Cell samples were taken at different time points after release
and cell-cycle progression was followed by ﬂow cytometry.
Samples were ﬁxed and examined under a ﬂuorescence
EGFP-hOGG1 anti-nucleolin Merge
EGFP-hOGG1 anti-BrdU Merge
A
B
Figure 2. Confocal laser scanning microscopy of EGFP-hOGG1. HeLa cells were transiently transfected with pEGFP-hOGG1 and fixed 24 h after transfection.
(A) Nucleoli were detected by staining with anti-nucleolin. Merged images show the localization of EGFP-hOGG1 in the nucleoli. (B) Replication foci were
visualized by pulsing the cells with BrdU. Merged images show that EGFP-hOGG1 is localized in the nucleoli during S-phase.
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Figure 3. Expression of EGFP, EGFP-hOGG1, EGFP-hOGG1-Cys
326 and
EGFP-hOGG1-Glu
326. An aliquot of 20 mg nuclear extracts from HeLa-
EGFP (lane 1), HeLa-EGFP-hOGG1 (lane 2), HeLa-EGFP-hOGG1-Cys
326
(lane 3) and HeLa-EGFP-hOGG1-Glu
326 (lane 4) cell lines were examined
by western blot analysis using (A) anti-GFP antibody and (B) anti-OGG1
antibody. Anti-GFP detected EGFP (30 kDa), EGFP-hOGG1 and all mutant
proteins(68kDa).Anti-OGG1detectedEGFP-hOGG1andthemutantproteins
(68kDa).(C)Formamidopyrimidineexcisionbyincreasingamountsofnuclear
extracts from HeLa-EGFP (closed diamonds), HeLa-EGFP-hOGG1 (closed
squares), HeLa-EGFP-hOGG1-Cys
326 (closed triangles) and HeLa-EGFP-
hOGG1-Glu
326 (closed circles).
1816 Nucleic Acids Research, 2005, Vol. 33, No. 6microscope. Immediately after the removal of nocodazole
most of the cells are in the G2 phase. At this time, EGFP-
hOGG1 is mainly distributed evenly throughout the nucleus
(Figure 4). Within the next 2 h, cells enter the M-phase, the
nuclear envelope disassembles and EGFP-hOGG1 associates
with chromatin (Figure 4). At 2–8 h after nocodazole removal
(data not shown), and at the time of double-thymidine block
release,thecells areinG1,andEGFP-hOGG1ismainlyhomo-
geneously distributed to the nucleus (Figure 4). However, as
the cells progress through the S-phase, 4 h after double-
thymidine block release, in most of the cells, EGFP-
hOGG1 accumulates within the nucleoli (Figure 4). In addi-
tion, to conﬁrm the localization of EGFP-hOGG1 to the nuc-
leoli during S-phase, we visualized sites of replication using
anti-BrdU antibodies. As shown in Figure 2B, EGFP-hOGG1
is associated with the nucleoli during S-phase. Control cells
carrying only EGFP stained green both in the cytoplasm and in
the nucleus throughout the cell cycle (data not shown).
The localization of EGFP-hOGG1 to the nucleoli is
linked to transcription
Actinomycin D speciﬁcally inhibits RNA polymerase I at low
concentrations (51). EGFP-hOGG1 cells were synchronized at
the G1/S boundary, released and allowed to enter S-phase
before being treated with 0.04 mg/ml actinomycin D for 4 h.
In addition to nucleolin, we examined the distribution of ﬁb-
rillarin and RNA polymerase I (RPA135) relative to EGFP-
hOGG1 in cells with or without actinomycin D. The staining
of nucleolin, ﬁbrillarin and RPA135 overlapped with the green
ﬂuorescence signal of EGFP-hOGG1 in S-phase cells
(Figure 5A–C, G–I and M–O). The staining of RNA poly-
merase I and ﬁbrillarin revealed dot-like structures in the
nucleoli (Figure 5H and N) that represent the ﬁbrillar com-
ponents of the nucleolus: the ﬁbrillar centre (FC) together with
the surrounding dense ﬁbrillar component (DFC). The FC
together with the surrounding DFC has been considered as
a functional unit for rRNA synthesis and processing
(52,53). Treatment with actinomycin D leads to the formation
of crescent-shaped structures (or caps) in nucleoli, as there is a
relocalization of nucleolar proteins whereby the ﬁbrillar com-
ponents are segregated from the granular components (54–56).
After actinomycin D treatment, both RPA135 and ﬁbrillarin
were redistributed as crescent-shaped structures in the segreg-
ated nucleoli, as was EGFP-hOGG1 (Figure 5J–L and P–R)
while most nucleolin and some EGFP-hOGG1 were dispersed
into the nucleoplasm (Figure 5D–F).
EGFP-hOGG1-Cys
326 is excluded from the nucleolus
during S-phase
EGFP fused to the C-terminal of hOGG1-Cys
326 was transi-
ently transfected into HeLa cells to compare its cellular loc-
alization with that of EGFP-hOGG1. As shownin Figure 6, the
Ser!Cys
326 polymorphism has a dramatic effect on the nuc-
lear localization of the protein. EGFP-hOGG1-Cys
326 is
excluded from the nucleoli as seen when cells were ﬁxed
and nucleoli were visualized with anti-nucleolin antibody.
A new mutant, EGFP-hOGG1-Ala
326, was produced to
address the question of whether the absence of the serine
residue or the presence of a cysteine residue was responsible
for the dramatic difference in the localization of the poly-
morphic allele. Transient transfection of HeLa cells with
EGFP-hOGG1-Ala
326 showed the distribution to be identical
to that of EGFP-hOGG1-Cys
326 indicating that the presence of
the serine residue is important for the correct localization of
hOGG1 to the nucleoli (data not shown).
The associations with interphasic chromatin and nuclear
matrix, and with mitotic condensed chromosomes
are disrupted in EGFP-hOGG1-Cys
326
To determine the distribution of EGFP-hOGG1-Cys
326 during
mitosis, we created stable cell lines overexpressing EGFP-
hOGG1-Cys
326. Nuclear extracts were tested for faPy DNA
glycosylase activity and results showed the fused enzyme to
be active (Figure 3C). EGFP-hOGG1-Cys
326 was excluded
from condensed chromosomes during mitosis (Figure 7A,
example of cells in pro-metaphase, metaphase and telophase,
respectively) as evidenced by counterstain with DAPI, in
contrast to EGFP-hOGG1, which has been previously
Figure 4. Dynamic subcellular relocalization of EGFP-hOGG1 during the cell
cycle in HeLa-EGFP-hOGG1 cells. HeLa-EGFP-hOGG1 parallel cell cultures
were synchronized by either nocodazole or double-thymidine block treatment.
Samples were harvested immediately after the removal of nocodazole (most of
thecellsareinG2phase),2hafternocodazoleremoval(cellsareinM-phase),at
the time of double-thymidine block release (cells are in G1 phase) and 4 h after
double-thymidineblockrelease(cellsareinS-phase).(A)Determinationofcell
cycle phases by flow cytometry. (B) Subcellular distribution of EGFP-hOGG1
analysed using an Axioplan 2 fluorescence microscope (Carl Zeiss). DNA was
labelled with DAPI staining.
Nucleic Acids Research, 2005, Vol. 33, No. 6 1817shown to co-localize with condensed chromatin in mitotic
cells (47). As EGFP-hOGG1 has been shown to be associated
with the soluble chromatin and the nuclear matrix during
interphase (47), we wanted to investigate whether these
associations were maintained for the EGFP-hOGG1-Cys
326
mutant protein. Accordingly, asynchronously dividing HeLa-
EGFP-hOGG1-Cys
326 cells were sequentially extracted to
obtain cytoplasm, soluble chromatin and nuclear matrix.
Figure 5. Effect of transcription inhibition by actinomycin D on the cellular distribution of EGFP-hOGG1. HeLa-EGFP-hOGG1 cells were grown on coverslips,
synchronized by double-thymidine block, allowed to enter the S-phase and treated with 0.04 mg/ml actinomycin D before being fixed and subjected to immuno-
fluorescence staining with the indicated antibodies. The cells were analysed using an Axioplan 2 fluorescence microscope (Carl Zeiss).
EGFP-hOGG1-Cys326 anti-nucleolin Merge
Figure 6. Confocal laser scanning microscopy of EGFP-hOGG1-Cys
326. HeLa cells were transiently transfected with pEGFP-hOGG1-Cys
326 and fixed 24 h after
transfection. Nucleoli were detected by staining with anti-nucleolin. Merged images showed that the EGFP-hOGG1-Cys
326 is excluded from the nucleoli.
1818 Nucleic Acids Research, 2005, Vol. 33, No. 6The protein extracts were analysed by using western
blotting. The fractionation procedure was controlled by
immunoblotting with antibodies directed against lamin
A/C, a nuclear matrix-associated protein, and histone H1,
a chromatin-associated protein (Figure 7C, lanes 2 and 4).
Immunoblotting with anti-hOGG1 antibody revealed EGFP-
hOGG1-Cys
326 to be present only in the cytoplasmic fraction
(Figure 7C, lane 1). This probably reﬂects protein leakage
from the nucleus during the cell lysis procedure. However,
no EGFP-hOGG1-Cys
326 could be detected in the soluble
chromatin or in the nuclear matrix fractions (Figure 7C,
lanes 2 and 4).
The EGFP-hOGG1-Glu
326 mutant displays a similar
cellular distribution to the wild-type protein
Since the Ser-326 is a potential site of phosphorylation as
predicted by the NetPhos 2.0 Protein Phosphorylation Predic-
tion Server (57), we wanted to examine whether the aberrant
localizationofEGFP-hOGG1-Cys
326couldbeduetothephos-
phorylation status of the serine. As glutamate can mimic phos-
phoserine (58,59), we constructed a pEGFP-hOGG1-Glu
326
mutant. A HeLa cell line stably expressing EGFP-hOGG1-
Glu
326 was generated and the subcellular localization was
examined throughout the cell cycle (Figure 3). Nuclear
extracts from these cells were tested for faPy DNA
Figure 7. EGFP-hOGG1-Cys
326 is excluded from mitotic chromosomes and its association with chromatin and nuclear matrix is disrupted, while EGFP-hOGG1-
Glu
326 is associated with the nucleoli, with the soluble chromatin fraction and the nuclear matrix. (A) HeLa-EGFP-hOGG1-Cys
326 cells were grown on coverslips
fixedandanalysedusinganAxioplan2fluorescencemicroscope(CarlZeiss).EGFP-hOGG1-Cys
326wasexcludedfrommitoticchromosomes.DAPIstainforDNA
showed the condensed chromosomes in the mitotic cells. (B) HeLa-EGFP-hOGG1-Glu
326 cells were grown on coverslips fixed and analysed using an Axioplan 2
fluorescencemicroscope(CarlZeiss).Nucleoliweredetectedbystainingwithanti-nucleolin.DAPIstainforDNAshowedthecondensedchromosomesinthemitotic
cells.EGFP-hOGG1-Glu
326isassociatedwiththenucleoli,withthesolublechromatinandthenuclearmatrix.(C)HeLa-EGFP-hOGG1-Cys
326and(D)HeLa-EGFP-
hOGG1-Glu
326cellsweresequentiallyextractedtoobtainacytoplasmicfraction,achromatinfraction,ahighsaltwashfractionandthenuclearmatrix.Proteinsfrom
equal cell equivalent from each fraction were analysed by western blotting with the indicated antibodies.
Nucleic Acids Research, 2005, Vol. 33, No. 6 1819glycosylase and results showed that the fused protein was
active (Figure 3C). As described for the wild-type protein,
EGFP-hOGG1-Glu
326 was transported to nucleoli during S-
phase (Figure 7B). Furthermore, during mitosis, from pro-
metaphase to telophase, the EGFP-hOGG1-Glu
326 signal was
co-localized with the condensed chromosomes (Figure 7B
shows examples of cells in pro-metaphase and in telophase).
Finally, we wanted to examine whether EGFP-hOGG1-Glu
326
would also be associated with the soluble chromatin and the
nuclear matrix. By sequentially extracting the cells to obtain
cytoplasm, soluble chromatin and the nuclear matrix, we were
able to show that EGFP-hOGG1-Glu
326 was associated with
both the soluble chromatin and the nuclear matrix fractions
(Figure 7D, lanes 2 and 4). The fractionation procedure was
controlled as described previously (Figure 7D). Interestingly,
the anti-phosphoserine recognized a phosphorylated form of
the enzyme in both EGFP-hOGG1 and EGFP-hOGG1-Glu
326
chromatin fractions.
EGFP/EYFP-hOGG1, EGFP-hOGG1-Cys
326 and
EGFP-hOGG1-Glu
326 localization during
S-phase in live cells
One of the advantages of using ﬂuorescent fusion proteins to
examine the subcellular localization of proteins is that live
cells can be viewed and followed with time-lapse imaging.
We investigated the fate of EYFP-hOGG1 during S-phase in
living cells using PCNA as a marker for replication foci as it
has been shown that ﬂuorescent-labelled-PCNA forms distinct
foci in S-phase cells that co-localize completely with endo-
genous PCNA and bromo-deoxyuridine incorporation (50,60).
We transiently co-transfected HeLa S3 cells with EYFP-
hOGG1 and ECFP-PCNA and followed the cells for 20 h.
Throughout S-phase, EGFP-hOGG1 is localized around the
nucleoli as shown in Figure 8A, which shows a cell during
S-phase. To compare the localization of EGFP-hOGG1,
EGFP-hOGG1-Cys
326 and EGFP-hOGG1-Glu
326 in living
cells during S-phase, stable cell lines were transiently trans-
fected with HcRed-PCNA. As shown in Figure 8B, EGFP-
hOGG1-Cys
326 is not associated with the nucleoli while
the localization of EGFP-hOGG1-Glu
326 looks similar to
the wild-type protein.
DISCUSSION
An increasing number of DNA repair proteins have been
shown to have cell-cycle-dependent expression, including
UNG2, RAD51, RAD52, APE, hNTH1, ANPG and hMYH
(48,61–65). Northern blot hybridization of synchronized
Figure 8. HeLacellsweretransientlytransfectedwithpEYFP-hOGG1andpECFP-PCNAtovisualizereplicationfoci,andindividualcellswereexaminedbytime-
lapse fluorescence microscopy. (A) A representative cell shown early in S-phase (T = 120 min) and 4 h later (T = 360 min). (B) HeLa-EGFP-hOGG1, HeLa-EGFP-
hOGG1-Cys
326 and HeLa-EGFP-hOGG1-Glu
326 cells were transiently transfected with HcRed-PCNA to visualize replication foci.
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of hOGG1 with increased transcription of the major nuclear
andmitochondrialisoformsduringS/G2(Figure1).Amongthe
predicted DNA-binding sites for transcription factors in the
HOGG1 promoter are two consensus sequences that poten-
tially bind NF-Y (position 1884–1897, accession no.
AJ131341) and E2F (position 1862–1869, accession no.
AJ131341).BothNF-YandE2Fhave beenshowntobecrucial
regulators of the cell-cycle-dependent expression of several
genes such as cdc2, CDC25, cyclin E, cyclin A, cyclin B,
topoisomerase IIa and A-myb transcription factor (66–70).
Moreover, although the murine and human OGG1 cDNAs
are well conserved (85% over the ORF), there is little homo-
logy between the promoter regions of the genes (46% over
2 kb upstreams of the translation start). However, the mouse
OGG1 gene also contains putative binding sites for NF-Y
(position 2028–2040) and E2F (positions 967–974 and
231–240). In contrast, a recent study in which the promoter
of HOGG1 was fused to the ﬁreﬂy luciferase gene carried out
in HeLa cells showed that the expression of the reporter gene
was not modulated during the cell cycle (71). As these experi-
ments have been carried out in a different cell line, the
participation of tissue-speciﬁc transcription factors in the tran-
scriptional cell-cycle-dependent regulation of HOGG1 cannot
be excluded.
We and others have tried to examine the intracellular distri-
bution of endogenous hOGG1 in different cell lines. However,
endogenoushOGG1isbarelydetectedusingtheantibodiesthat
arepresentlyavailable[(23)andL.Luna,M.Bjøra ˚s,V.Rolseth
and E. Seeberg, unpublished data]. We, therefore, used the
EGFP tag to study the subcellular localization of hOGG1.
Using this approach we showed that EGFP-hOGG1 was relo-
calized during the cell cycle and it was associated with the
nucleoliduringS-phaseandwithcondensedchromosomesdur-
ing mitosis. The method by which cells were ﬁxed (formalin,
PFA or ethanol) had an effect on the localization of EGFP-
HOGG1 within the nucleoli as can be seen when comparing
Figures 2 and 5–8. In live cells, EGFP-hOGG1 appeared to be
concentratedaroundthenucleoliwhileinﬁxedcellsitappeared
tohave‘leaked’intothenucleolus.Thishasalsobeenobserved
inotherproteinslikethehigh-mobilitygroupboxproteins1and
2 (HMGB1 and HMGB2) (72).
Some insights into the biological role of hOGG1 might be
gained by examining putative role(s) of hOGG1 in the nuc-
leolus. Ribosomal DNA is relatively GC-rich and it has been
showntobeverysensitivetoionizingradiation(73).However,
only a few studies have been carried out to investigate both the
extent and the repair of DNA damage of rDNA in mammals.
The severe hereditary progeroid disorder Cockayne syndrome
is a consequence of a defective transcription-coupled repair
(TCR) pathway. Some key players in TCR, such as the Cock-
ayne syndrome A (CSA) and B (CSB) proteins have been
identiﬁed (74). Recently, Egly and co-workers (75) showed
that CSB is found in the nucleolus within a complex that
includes RNA pol I, TFIIH and XPG. At the same time,
Bohr and co-workers (76) reported a functional cross-talk
between CSB and hOGG1. As neither a functional nor a phys-
ical direct interaction was detected between these two pro-
teins, the authors hypothesize a protein complex containing
among others CSB and hOGG1. Likewise, the protein coded
for the XRCC1 gene participates in DNA single-strand breaks
and in BER by its interaction with several of the enzymes
involved in these processes. XRCC1 has been shown to be
localized to the nucleolus and to physically interact with
hOGG1 (77–80). Thus, we can picture a situation where
multi-protein complexes composed of various combinations
of polypeptides coexist in the nucleoli. The composition of
these complexes depends on transient protein–protein interac-
tions that most probably vary during cell-cycle progression
and/or under speciﬁc conditions such as post-translational
modiﬁcations. The actinomycin D inhibition results that
show relocalization of EGFP-hOGG1 together with ﬁbrillarin
and polI to the caps in the segregated nucleoli strengthens the
idea of a multimodular complex. This brings us to the ques-
tion: is hOGG1part of a complexof proteins that have a role in
maintaining the integrity of rDNA, or are nucleoli simply a
storage place for these proteins. Thus, the nucleolus might be a
sequestering compartment of hOGG1 to avoid the accumula-
tion ofGC!TAtransversions owing tothe removal of8-oxoG
from 8-oxoG:A. Post-replicative repair of DNA mispairs is
critical for effective maintenance of the genome. Thus, com-
partmentalization of hOGG1 to the nucleoli during S-phase
might increase the repair efﬁciency of A:8-oxoG mispairs that
arise during DNA replication, as dCMP or dAMP can be
selectively incorporated opposite 8-oxoG (7). Accordingly,
it has been shown that hMYH, an adenine-speciﬁc glycosylase
responsible for removal of the mispaired adenine, localizes
to the nucleus and during S-phase associates speciﬁcally with
the replication foci for immediate post-replicative repair of
adenine mispaired with 8-oxoG (64).
Nuclear localization signals (NLSs) are short stretches of
amino acids that mediate the transport of nuclear proteins
into the nucleus. NLSs are classiﬁed into three categories;
the best studied are mono- and bi-partite motifs (81). Several
sequences in a different number of proteins have been deﬁned
as nucleolus localization signals (NoLSs). In contrast to NLSs,
there are no simple NoLSs and it has been proposed that
localization of proteins to the nucleolus may occur through
a variety of mechanisms (82). The nuclear localization of
hOGG1 has shown to be driven by an NLS situated in the
C-terminal segment of the protein (21). The serine to cysteine
326 mutation did not affect the nuclear localization of the
protein; however, the association with the nuclear matrix
and the chromatin, the nucleoli localization during S-phase
and co-localization to the condensed chromosomes during
mitosis were altered. As there appears to be no NoLS con-
sensus similar to a mitochondrial or peroxisomal localization
sequences, a scenario has emerged in which a nucleolar pro-
tein might have an interaction that causes it to be localized to
the nucleolus. Thus, we suggest that the Ser-326 has to be
phosphorylated to interact with a protein during S-phase that
will translocate EGFP-hOGG1 to the nucleolus and to the
condensed chromosomes during mitosis. Supporting this
idea is the restoration of wild-type localization of the
EGFP-hOGG1-Glu
326 mutant protein that mimicked a phos-
phorylated serine. A link between aberrant protein localization
and cancer has been established by several studies that include
BRCA1, p53, APC and RCAS1 (83–87). A recent report has
shown that the hOGG1-Cys
326 protein has a lower ability to
suppress mutations than the hOGG1-Ser
326 protein in human
cells in vivo (88). We suggest that the difference in the
mutation suppressive ability between the two polymorphic
Nucleic Acids Research, 2005, Vol. 33, No. 6 1821hOGG1 proteins is due to the subnuclear localization brought
about by a phosphorylation of the Ser-326.
Finally, we had identiﬁed a phosphorylated form of EGFP-
hOGG1 in the chromatin fraction by western blotting using a
phosphoserine-speciﬁc antibody (47). Interestingly, this form
was still present in the chromatin fraction isolated from HeLa-
EGFP-hOGG1-Glu
326 but it was clear that this antibody did
not recognize the mimicked phosphorylated Ser-326. We,
therefore, suggest that an additional phosphorylation on a
different serine is responsible for the association of the protein
with the chromatin fraction. Further studies are needed to
elucidate the complete phosphorylation status of hOGG1
during the cell cycle.
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